Comparative Pharmacology
Head-to-head clinical analysis: INBRIJA versus SYMMETREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INBRIJA versus SYMMETREL.
INBRIJA vs SYMMETREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
INBRIJA (levodopa inhalation powder) is a combination of levodopa, an aromatic amino acid, and a prodrug of dopamine, which is decarboxylated to dopamine in the brain, thereby restoring dopamine levels in the striatum and improving motor function in Parkinson disease.
Inhibits influenza A virus uncoating and viral RNA replication; increases dopamine release and blocks dopamine reuptake in the CNS.
Inhaled levodopa powder, 84 mg (two 42 mg capsules) inhaled orally via the INBRIJA inhaler as needed for OFF episodes, up to 5 times per day. Maximum daily dose: 420 mg (5 doses).
100 mg orally twice daily; may increase to 200 mg orally twice daily if tolerated, usually in divided doses. For Parkinson's disease, 100 mg orally twice daily; for drug-induced extrapyramidal reactions, 100 mg orally twice daily.
None Documented
None Documented
0.75–1.5 hours (terminal elimination half-life of levodopa). Short half-life necessitates frequent dosing or continuous dopaminergic stimulation strategies.
Terminal half-life: 24-48 hours (young adults); 48-72 hours (elderly); may extend to 7-10 days in severe renal impairment. Clinically, steady-state achieved in 4-7 days.
Primarily renal excretion of metabolites and unchanged drug. Approximately 80% of a dose is recovered in urine as levodopa metabolites (mainly 3-O-methyldopa and vanilpyruvic acid) and <10% as unchanged levodopa. Fecal excretion accounts for <5%.
Primarily renal excretion (90-95% unchanged) via glomerular filtration and tubular secretion; minor fecal (<5%). Dose adjustment required in renal impairment.
Category C
Category C
Antiparkinsonian
Antiviral and Antiparkinsonian